Vanda Pharmaceuticals Inc. (VNDA) Downgraded by Zacks Investment Research
Zacks Investment Research downgraded shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) from a strong-buy rating to a hold rating in a research report released on Thursday morning.
According to Zacks, “Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It’s second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It’s third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. “
VNDA has been the topic of several other reports. Jefferies Group LLC reiterated a buy rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Oppenheimer Holdings, Inc. reiterated a buy rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, September 14th. Piper Jaffray Companies reiterated an overweight rating and set a $23.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, June 27th. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 3rd. Finally, BidaskClub upgraded shares of Vanda Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, August 22nd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Vanda Pharmaceuticals presently has an average rating of Buy and an average target price of $21.63.
Vanda Pharmaceuticals (VNDA) traded up 0.87% during midday trading on Thursday, hitting $17.35. The stock had a trading volume of 445,138 shares. The firm has a 50 day moving average price of $17.40 and a 200 day moving average price of $15.56. Vanda Pharmaceuticals has a one year low of $12.70 and a one year high of $18.99. The stock’s market cap is $778.29 million.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The firm had revenue of $42.06 million for the quarter, compared to analysts’ expectations of $40.31 million. During the same period in the previous year, the company posted $0.01 EPS. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities analysts expect that Vanda Pharmaceuticals will post ($0.42) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Vanda Pharmaceuticals Inc. (VNDA) Downgraded by Zacks Investment Research” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/08/vanda-pharmaceuticals-inc-vnda-downgraded-by-zacks-investment-research.html.
Several institutional investors have recently bought and sold shares of VNDA. Legal & General Group Plc grew its holdings in shares of Vanda Pharmaceuticals by 37.4% during the 2nd quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after acquiring an additional 3,022 shares in the last quarter. Virginia Retirement Systems ET AL purchased a new position in shares of Vanda Pharmaceuticals during the 1st quarter valued at $193,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Vanda Pharmaceuticals during the 1st quarter valued at $196,000. Kopp Investment Advisors LLC purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $196,000. Finally, American International Group Inc. grew its holdings in shares of Vanda Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 22,563 shares of the biopharmaceutical company’s stock valued at $316,000 after acquiring an additional 1,491 shares in the last quarter. Institutional investors and hedge funds own 86.49% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.